ARC
STML

Absolute Return Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Absolute Return Capital’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-25,800
Closed -$378K – 1051
2014
Q2 		$378K Buy
+25,800
New +$396K ﹤0.01% 894

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Absolute Return Capital's STML Position: Q3 2014 in Review

Absolute Return Capital sold out of Stemline Therapeutics, Inc. (STML) in Q3 2014, closing a stake of 25,800 shares — an estimated $378K sold.

Absolute Return Capital first reported a position in STML in Q2 2014 and held it in 1 quarter. The position peaked at $378K in Q2 2014. 61 funds tracked by Wall St. Rank hold STML as of Q3 2014.

  • Absolute Return Capital reported no remaining Stemline Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 25,800 Stemline Therapeutics, Inc. shares in Q3 2014, an estimated $378K.
  • Absolute Return Capital first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Stemline Therapeutics, Inc. position peaked at $378K in Q2 2014.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.